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A wide variety of phospholipase A, inhibitors blocks intra-Golgi protein transport reconstituted in a cell-free system. Phospholipase A2 activity 
detectable under the protein transport assay conditions is actually inhibtted by the inhibitors. There is a good correlation between the inhibition 
of protein transport and that of phospholipase Az activity. Prolactin secretion from GH, cells is also blocked by a membrane-permeable 
phosphohpase AZ inhibitor, suggesting the physiological relevance to mhibition of protem transport in vitro by phospholipase A, inhibitors. 
Protein transport: Phospholipase A?: Prolactm secretion: GH, cell 
1. INTRODUCTION 
Intracellular protein traffic from the endoplasmic 
reticulum to the cell surface through the Golgi appara- 
tus is mediated by the vesicles which transit between the 
organelles [l]. Each transport process includes vesicle 
budding, targetting, and fusion [24]. This implies that 
a membrane bilayer is split and two membranes are 
fused into one cycle of the transport reaction. However, 
little is known about the nature or origins of the force 
which perturbs biological membranes and finally pro- 
motes their fission and fusion. 
acceptor Golgi fraction. When the donor and acceptor 
Golgi membrane fractions were incubated with ATP 
and a cytosolic fraction, vesicles containing VSV-G pro- 
tein are formed from the donor Golgi fraction and 
moved to the acceptor fraction [l 11. Fusion of the vesi- 
cles is detectable by the transfer of [3H]GlcNAc from 
UDP-[3H]GlcNAc via the reaction catalyzed by UDP- 
GlcNAc transferase I in the medial compartment of the 
acceptor Golgi fraction. 
Based on the studies using inhibitors, it has been 
proposed that phospholipase A, is involved in the ex- 
ocytotic pathways [5-71. Recently, Morgan and Bur- 
goyne [8] found that the release of catecholamine from 
permeabilized chromaffin cells is enhanced by a protein 
named Exo I, which shares sequence homology with the 
14-3-3 family of proteins. One member of this family 
was cloned and turned out to be a phospholipase A, [9]. 
Keeping these results in mind, we have tested the effect 
of phospholipase A, inhibitors on a well-characterized 
intra-Golgi protein transport system reconstituted in a 
cell-free system [IO]. This system reconstitutes the trans- 
port of VSV-G protein from the cis compartment of a 
donor Golgi fraction to the medial compartment of an 
We report here a correlation between the inhibition 
of intra-Golgi protein transport in vitro and that of 
phospholipase A, activity. Protein secretion in vivo is 
also blocked by a membrane-permeable phospholipase 
A2 inhibitor. 
2. MATERIALS AND METHODS 
Correspondence uddress: M. Tagaya. Institute of Scientific and Indus- 
trial Research, Osaka University, Ibaraki. Osaka 567. Japan. Fax: (81) 
(6) 876 4194. 
Brefeldin A and manoalide were obtained from Wako Chemicals. 
p-Bromophenacyl bromide and fatty acids were obtained from Naca- 
lai Tesque. NDGA and (p-amylcinnamoyl)anthramlic acid were pur- 
chased from Biomol Research Laboratories. Eicosatetraynoic acid 
and S-hydoxyeicosatetraen-1-01~ acid were from Cascade Biochem. 
UDP-[‘H]GlcNAc (6.1 Ci/mmol). I-stearoyl-2-[r4C]arachidonyl-sn- 
glycero-3-phospho rylch oline (55.6 mCi/mmol) and ENZHANCE 
were from DuPont-New England Nuclear. (?S]Methionine was from 
ICN Radiochemicals. ER-3826 was a gift from Eisai Co. Anti-pro- 
lactm rabbit serum (HAC-RT26-OlRBP85) was a generous gift from 
Dr. K. Wakabayashi at Gunma University. Donor and acceptor Golgi 
fractions were prepared from VSV-infected CHO 15B and wild-type 
CHO cells. respectively, as described by Balch et al. [lo]. Bovine bram 
cytosol was prepared as described by Malhotra et al. [12]. 
Abbreviutlons. XV-G protein. vesicular stomatitis virus-encoded 
glycoprotein: NDGA. nordihydroguaiaretic acid: GlcNAc. N-ace- 
tylglucosamine; ICY,,, the concentration required for 50% mhtbition. 
The Golgi protem transport assay was carried out as described by 
Balch et al. [lo]. The standard assay mixture (50~1) consists of25 mM 
HEPES (pH 7.0) containing 15 mM KCI. 2.5 mM magnesium acetate, 
0.5 mM dithiothreitol. an ATP-regenerating system (5 mM creatine 
phosphate, 0.25 mM UTP, 0.05 mM ATP, and 12 U/ml creatme 
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phosphokinase). 0.64 PM (0.2 &I) UDP-[‘H]GlcNAc, 1.5 mg/ml bo- 
vine bram cytosol. The assay was performed for 1 h at 37°C. and then 
WV-G protein was immunoprecip1tated. collected on filters and 
counted. All the inhtb1tors used in this study were dissolved 1n di- 
methyl sulfoxide at appropriate concentrations. p-Bromophenacyl 
bromide was dissolved before use. because thts compound decomposes 
m the solvent. The final concentration of dtmethyl sulfox1de in the 
assay mtxture was 1% (v/v) This concentration of dtmethyl sulfox1de 
alone did not markedly mh1b1t the transport assay. 
The assay cond1trons for phospholipase Al acttvity were the same 
as those for 1ntra-Golg1 protein transport except that 9pM (0.025,K1) 
1 -stearoyl-2-[‘~C]arach1donyl-srz-glycero-3-phosphorylcholine was in- 
cluded instead of UDP-[‘H]GlcNAc. After mcubat1on at 37°C for 2 
h. the reaction was termmated by the addition of 0.35 ml of Dole 
reagent (1sopropanol/heptane/l N H,SO,, 78:20:2) [13]. One hundred 
yl ofwater and 0 15 ml heptane were then added. and the solution was 
mtxed vigorously by vortexing. After centr1fugat1on at 1.500 x g for 
3 mm, 0.14 ml of the upper phase was removed and mixed with 0.35 
ml of heptane and 30 mg of sihcic acid powder After centrlfugation 
at 1,500 x g for 3 min. 0.4 ml of the heptane phase was used for the 
measurement of rad1oacttvrty 
The method for measurmg prolacttn secretion from GH, cells ~111 
be described elsea here. 
3. RESULTS AND DISCUSSION 
We tested the effect of compounds known to inhibit 
phospho-lipase A, on the intra-Golgi protein transport 
reconstituted in a cell-free system. These include irre- 
versible and reversible phospholipase A1 inhibitors, un- 
saturated fatty acids, and dual inhibitors for cyclooxy- 
genase and lipoxygenases. All the compounds used 
inhibited the transport assay. Table 1 summarizes the 
concentrations required for 50% inhibition (IC,,). IC,,, 
values for irreversible and reversible phospholipase Al 
inhibitors were comparable to those required for inhibi- 
tion of phospholipase A2 [14-171. Although ER-3826 is 
a strong inhibitor for membrane-bound phospholipase 
Table 1 
Effect of phosphol1pase AZ mhtbitors on mtra-Golgi protein transport 
in vttro 
Compound I’%, (PM) 
Irreversrble phosphohpase A, InhIbitor 
p-Bromophenacyl bromide 
Manoahde 









Dual InhIbitor for cyclooxygenase and lipoxygenases 
NDGA 
Etcosatetraynoic acid 













A, from rabbit heart [lg], this compound was not effec- 
tive. Dexamethasone. known to inhibit phospholipase 
A2 by production of the phospholipase A, inhibitory 
protein lipocortin in vivo [ 191 was ineffective (IC,,, = 0.4 
mM). It was reported that phospholipase A, is inhibited 
by unsaturated fatty acids such as arachidonic acid. but 
not by saturated fatty acids [20,21]. Unsaturated fatty 
acids (oleic, linoleic. and arachidonic acids) inhibited 
the intra-Golgi protein transport assay, whereas satu- 
rated fatty acids (stearic and arachidic acids) had no 
effect up to 40 PM. Since the critical micelle concentra- 
tions of unsaturated fatty acids are higher than those of 
the saturated fatty acids having the same number of 
carbon atoms [22], this inhibition by the unsaturated 
fatty acids is not due to the nonspecific damage of Golgi 
membranes. Because cyclooxygenase and lipoxygenases 
utilize arachidonic acid, dual inhibitors for the two en- 
zymes may act as phospholipase A, inhibitors. In fact, 
NDGA and eicosatetraynoic acid, both known as the 
dual inhibitors, were good inhibitors for the intra-Golgi 
protein transport assay. It is unlikely that prosta- 
grandins and leukotrienes, which are produced through 
the reactions catalyzed by cyclooxygenase and lipoxyge- 
nases. respectively, regulate intra-Golgi protein trans- 
port. Because indomethacin and caffeic acid, the inhib- 
itors specific for cyclooxygenase and lipoxygenases, 
respectively, were much less inhibitory than the dual 
inhibitors (indomethacin : IC,, = 100 PM, caffeic acid, 
no inhibition up to 0.2 mM). In addition, 5-hydroxy- 
eicosatetraen-1-oic acid, an intermediate for leukotriene 
biosynthesis, had inhibitory effect. 
To examine whether phospholipase A2 is actually in- 
hibited by the phospholipase A, inhibitors used, we 
Complete Golgi Cytosol +EGTA 
Fig 1 Phosphohpase A, activtty detectable under the protein trans- 
port assay conditions. The assay mrxture contains an ATP-regenerat- 
tng system. Golg1 membranes, and bovme brain cytosol (Complete). 
an ATP-regenerattng system and Golg~ membranes (Golgi). or an 
ATP-regenerating system and bovine bram cytosol (Cytosol). 2 mM 
EGTA was added to the complete assay mixture (+EGTA). Addtt1on 
of an ATP-regeneratmg system activated phosphohpase A, activity by 
1 3- to 1 6-fold compared with its absence. Data are expressed as the 
mean of two experiments. 
Volume 324, number 2 FEBS LETTERS June 1993 
measured its activity by using an exogeneous substrate, 
l-stearoyl-2-[14C]arachidonyl-sn-phosphorylcholine. Fig. 1 
shows that phospholipase A, activity detectable under 
the transport assay conditions is mainly located in a 
cytosolic fraction and some in Golgi membranes. This 
phospholipase A, activity was not inhibited by EGTA. 
Although most phospholipase A,s absolutely require 
Cal+ for activity, several species of cytosolic phospho- 
lipase A, recently found possess basal activity without 
Ca2+ [23-261. 14333 protein, which shares sequence 
homology with Exo I involved in exocytosis [S], is acti- 
vated by Ca’+, but the cation is not essential for the 
enzyme to exhibit phospholipase A2 activity [27]. The 
fact that the phospholipase A, activity detectable under 
the protein transport assay conditions is not inhibited 
by EGTA is consistent with the observation that EGTA 
does not inhibit the protein transport assay [28]. 
We found that phospholipase A2 activity detectable 
under the protein transport assay conditions was actu- 
ally inhibited by the phospholipase A, inhibitors up to 
70 to 80%. When IC,, values for phospholipase A, were 
plotted against IC,, values for protein transport, a good 
linear relationship was observed (Fig. 2). IC,, values for 
phospholipase A, were two- to threefold higher than 
those for protein transport. This difference may be 
attributable to the difference in substrate and/or its 
concentrations for the two reactions. 1-stearoyl-2- 
arachidonyl-sn-glycero-3-phosphoryl-choline is the ex- 
ogenous substrate for measuring phospholipase A, ac- 
tivity, whereas the Golgi membrane is the endogenous 
substrate for protein transport. The concentration of 
lipids in the Golgi membrane usable for phospholipase 
A, may be lower than 9 ,uM, the concentration of ex- 
ogenous substrate. 
0’ I 
0 20 40 60 00 
‘%o 
FOR TRANSPORT ( p M) 
Fig. 2. Correlatton between IC,, for protem transport and IC,,, for 
phospholipase AZ activity. Reversible and irreversible phosphohpase 
Az Inhibitors (p-bromophenacyl bromrde, manoahde. (p-amylcmnam- 
oyl)anthranilic acid, and ER-3826) (0). unsaturated fatty actds (oletc. 
linoleic. and arachidomc actds) (0). and dual inhibitors for cyclooxy- 
genase and lipowygenases (NDGA and eicosatetraynotc acid) (A). The 
line was drawn by the least-squares best fit method. 
To test the physiological relevance to inhibition of 
protein transport in vitro by phospholipase A, inhib- 
itors, we examined the effect of NDGA, a membrane- 
permeable phospholipase A, inhibitor. on prolactin se- 
cretion from GH, cells. As shown in Fig. 3, NDGA 
blocked prolactin secretion with an IC,, value of 60 PM, 
whereas dexamethasone had no significant effect up to 
200 yM. These results are consistent with the efficacy 
of the two compounds as inhibitors for protein trans- 
port in vitro. Reversibility of inhibition by NDGA sug- 
gests that the reagent does not seriously damage GH, 
cells and allows us to carry out a two-stage assay for 
investigating the step(s) inhibited by NDGA (Fig. 4). In 
stage I, pulse-labeled GH, cells were chased for 1 h in 
the presence or absence of NDGA. In stage II, the cells, 
after washing, were incubated for another 2 h in the 
presence or absence of brefeldin A. Brefeldin A blocks 
several steps of secretion, but does not affect step(s) 
after exocytotic vesicles and granules are formed [29]. 
In stage I, NDGA inhibited the secretion of prolactin 
by 70% ((65%-19%)/65%). When NDGA was removed, 
61% of the total prolactin labeled was secreted in stage 
II. However, brefeldin A still significantly inhibited the 
secretion by 45% ((61%-33%)/61%). These results sug- 
gest that NDGA inhibits step(s) before the formation of 
secretory vesicles, possibly transport from endoplasmic 
reticulum to Golgi and/or intra-Golgi transport. Incom- 
plete inhibition by brefeldin A in stage II is probably 
due to incomplete inhibition by NDGA in stage I. With 
19% secretion of labeled prolaction (Fig. 4), some frac- 
tions may have passed the final brefeldin A-sensitive 
step in stage I. 
In conclusion. the present results demonstrated a cor- 
relation between phospholipase A2 activity and intra- 
Golgi protein transport in vitro. Although we cannot 
0 
z 
Fig. 3. Effect of NDGA on prolactm secretron from GH, cells. Pro- 
lactin secretron from GH, cells was measured m the presence of van- 
ous concentrations of NDGA (0) and dexamethasone (cm). Values are 
the rdtlOS of the amounts of prolactm secreted in the presence of each 
inhibitor to that of prolactm secreted in a control experiment. Data 
are expressed as the mean of two experiments 
203 
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Fig. 4. NDGA inhibits step(s) prtor to the brefeldin A-resistant step(s) 
in prolactin secretion. Two-stage assay. GH, cells were pulse-labeled, 
and then chased at 37°C for 1 h m the presence or absence of 75 PM 
NDGA (stage I) The cells were washed with phosphate buffered 
saline to remove NDGA and then further incubated at 37°C for 3 h 
in the presence or absence of brefeldin A (BFA). Values are the ratios 
of the amounts of prolactin secreted to those of the total [“Slprolactm 
in stage I (3) and stage II (m). Data are expressed as the mean of two 
expenments. 
completely exclude the possibility that the inhibition of 
the protein transport is the consequence of that of other 
enzymes and/or proteins, use of several different types 
of inhibitors with no structural correlation may justfy 
our conclusion. By using phospholipase AZ inhibitors 
different from those used by us, Stahl and his colleagues 
recently found that phospholipase A, activity is re- 
quired for endosome fusion (personal communication). 
Phospholipase A, may be generally involved in intracel- 
lular protein traffic. This interesting possibility remains 
to be elucidated directly. 
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